0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TRAIL R2

TRAIL R2

Brief Information

Name:Tumor necrosis factor receptor superfamily member 10B
Target Synonym:Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-In
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

TR2-H5255-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TR2-M52H5-ELISA
Mouse TRAIL R2, His TagMouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) ELISA bioactivity

Immobilized Human TNFSF10 at 2 μg/mL (100 μL/well) can bind Mouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) with a linear range of 0.039-0.625 μg/mL (QC tested).

Synonym Name

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

Background

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain.  TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) Phase 2 Clinical Shenzhen Binder Biotechnology Co Ltd Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular Details
JCT-205 JCT-205 Phase 1 Clinical Inhibrx Adenocarcinoma Details
Eftozanermin alfa APG-350; APG-880; ABBV-621; PR-1625011 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Multiple Myeloma Details
GEN-1029 iDD-004; GEN-1029; Hx-DR5-01; Hx-DR5-05 Phase 2 Clinical Idd Biotech Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) Phase 3 Clinical Shenzhen Xinpeng Biology Engineering Co Ltd Neoplasms Details
Conatumumab AMG-655 Phase 2 Clinical Amgen Inc Ovarian Neoplasms; Solid tumours; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Pancreatic Neoplasms; Sarcoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Circularly permuted TRAIL (Beijing Sunbio Biotech) Phase 3 Clinical Beijing Shadong Biotech Co Ltd Multiple Myeloma Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) CTB-006 Phase 1 Clinical Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd Solid tumours Details
Dulanermin (Shanghai GeBaiDe) Phase 3 Clinical Shanghai Gebaide Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
BI-905711 BI-905711 Phase 1 Clinical Boehringer Ingelheim Gmbh Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms Details
Oba-01 Oba-01; Oba01 Phase 1 Clinical Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop